110 related articles for article (PubMed ID: 1468696)
1. Comparison of U-73,975 and cisplatin cytotoxicity in fresh cervical and ovarian carcinoma specimens with the ATP-chemosensitivity assay.
Hightower RD; Sevin BU; Perras JP; Untch M; Angioli R; Ramos R; Averette H
Gynecol Oncol; 1992 Nov; 47(2):186-90. PubMed ID: 1468696
[TBL] [Abstract][Full Text] [Related]
2. In vitro evaluation of the novel chemotherapeutic agents U-73,975, U-77,779, and U-80,244 in gynecologic cancer cell lines.
Hightower RD; Sevin BU; Perras J; Nguyen H; Angioli R; Untch M; Averette H
Cancer Invest; 1993; 11(3):276-82. PubMed ID: 8485650
[TBL] [Abstract][Full Text] [Related]
3. Chemosensitivity to the new anthracycline pirarubicin and other chemotherapeutic agents in primary and recurrent ovarian tumors in vitro.
Untch M; Sevin BU; Perras JP; Angioli R; Baibl A; Nguyen HN; Hightower RD; Averette HE
Gynecol Oncol; 1992 Nov; 47(2):172-8. PubMed ID: 1468695
[TBL] [Abstract][Full Text] [Related]
4. [Relationship between the expression of P-glycoprotein, glutathione S-transferase-pi and thymidylate synthase proteins and adenosine triphosphate tumor chemosensitivity assay in cervical cancer].
Gao GL; Wan HY; Zou XS; Chen WX; Chen YQ; Huang XZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Mar; 42(3):201-5. PubMed ID: 17537309
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
Andreotti PE; Cree IA; Kurbacher CM; Hartmann DM; Linder D; Harel G; Gleiberman I; Caruso PA; Ricks SH; Untch M
Cancer Res; 1995 Nov; 55(22):5276-82. PubMed ID: 7585588
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of paclitaxel (taxol), cisplatin, and the combination paclitaxel-cisplatin in ovarian cancer in vitro with the ATP cell viability assay.
Untch M; Sevin BU; Perras JP; Angioli R; Untch A; Hightower RD; Koechli O; Averette HE
Gynecol Oncol; 1994 Apr; 53(1):44-9. PubMed ID: 7909786
[TBL] [Abstract][Full Text] [Related]
7. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
8. Characterization of in vitro chemosensitivity of perioperative human ovarian malignancies by adenosine triphosphate chemosensitivity assay.
Gerhardt RT; Perras JP; Sevin BU; Petru E; Ramos R; Guerra L; Averette HE
Am J Obstet Gynecol; 1991 Aug; 165(2):245-55. PubMed ID: 1872324
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of the ATP chemosensitivity assay in epithelial ovarian cancer.
O'Meara AT; Sevin BU
Gynecol Oncol; 2001 Nov; 83(2):334-42. PubMed ID: 11606094
[TBL] [Abstract][Full Text] [Related]
10. Correlation of drug response with the ATP tumorchemosensitivity assay in primary FIGO stage III ovarian cancer.
Konecny G; Crohns C; Pegram M; Felber M; Lude S; Kurbacher C; Cree IA; Hepp H; Untch M
Gynecol Oncol; 2000 May; 77(2):258-63. PubMed ID: 10785475
[TBL] [Abstract][Full Text] [Related]
11. Chemical enhancement of cisplatin cytotoxicity in a human ovarian and cervical cancer cell line.
Boike GM; Petru E; Sevin BU; Averette HE; Chou TC; Penalver M; Donato D; Schiano M; Hilsenbeck SG; Perras J
Gynecol Oncol; 1990 Sep; 38(3):315-22. PubMed ID: 2121626
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity testing of a novel platinum analog, nedaplatin (254-S), in human gynecological carcinomas: a comparison with cisplatin.
Koshiyama M; Kinezaki M; Uchida T; Sumitomo M
Anticancer Res; 2005; 25(6C):4499-502. PubMed ID: 16334133
[TBL] [Abstract][Full Text] [Related]
13. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
Sevin BU; Perras JP
Am J Obstet Gynecol; 1997 Apr; 176(4):759-66; discussion 766-8. PubMed ID: 9125599
[TBL] [Abstract][Full Text] [Related]
14. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
15. In vitro evaluation of a novel chemotherapeutic agent, Adozelesin, in gynecologic-cancer cell lines.
Nguyen HN; Sevin BU; Averette H; Perras J; Hightower R; Ramos R; Donato D; Penalver M
Cancer Chemother Pharmacol; 1992; 30(1):37-42. PubMed ID: 1586978
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of titanocenedichloride versus cisplatin and doxorubicin in primary and recurrent epithelial ovarian cancer.
Kurbacher CM; Mallmann P; Kurbacher JA; Sass G; Andreotti PE; Rahmun A; Hübner H; Krebs D
Anticancer Res; 1994; 14(5A):1961-5. PubMed ID: 7847834
[TBL] [Abstract][Full Text] [Related]
17. [Chemosensitivity testing of topotecan as second-line agent in chemotherapy of ovarian cancer].
Qian XL; Peng ZL; Liu SL
Ai Zheng; 2003 Dec; 22(12):1352-4. PubMed ID: 14693068
[TBL] [Abstract][Full Text] [Related]
18. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of adenosine triphosphate bioluminescence assay for chemosensitivity testing of ovarian cancer cell line].
Shi W; Gu M; Liang L
Zhonghua Fu Chan Ke Za Zhi; 1996 Feb; 31(2):79-82. PubMed ID: 8758798
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
